Skip to main content

Table 2 Univariate and multivariate analysis with respect to progression free survival in 177 all breast cancers

From: Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression

Parameters Univariate analysis Multivariate analysis
Hazard ratio 95% CI p value Hazard ratio 95% CI p value
Subtype
TNBC vs non-TNBC
1.213 0.577–2.550 0.611 0.849 0.387–1.861 0.683
Subtype
HER2+BC vs non-HER2+BC
0.421 0.147–1.206 0.107 0.552 0.181–1.686 0.297
Lymph node status
Positive vs negative
4.157 0.990–17.456 0.052 4.330 1.027–18.263 0.046
Pathological response
pCR vs Non-pCR
0.611 0.279–1.336 0.217 0.854 0.352–2.072 0.728
PD-1
Positive vs negative
2.752 1.300–5.826 0.008 1.415 0.526–3.811 0.492
PD-L1
Positive vs negative
3.194 1.544–6.607 0.002 2.613 0.879–7.766 0.084
  1. CI confidence interval, TNBC triple-negative breast cancer, HER2 human epidermal growth factor receptor 2, BC breast cancer, pCR pathological complete response, PD-1 programmed cell death-1, PD-L programmed cell death-ligand